Apoglyx is developing first-in-class oral therapies for type 2 diabetes and acute pancreatitis using aquaporin inhibitors, which target specific protein channels involved in fluid regulation and inflammation. This approach aims to improve patient outcomes by addressing the underlying mechanisms of these conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Type 2 diabetes and acute pancreatitis are complex conditions with significant unmet needs. Current treatments may not fully address the underlying mechanisms of these diseases, leading to suboptimal patient outcomes. Inflammation and fluid regulation imbalances play a critical role in the progression of both conditions.
Solution
Apoglyx is developing first-in-class oral therapies for type 2 diabetes and acute pancreatitis, utilizing aquaporin inhibitors to target specific protein channels involved in fluid regulation and inflammation. Aquaporins, a family of thirteen isoforms, are implicated in various diseases, including cancer, diabetes, malaria, and autoimmunity. By selectively inhibiting specific aquaporin isoforms, Apoglyx aims to restore fluid balance and reduce inflammation, addressing the root causes of these conditions. This targeted approach has the potential to improve patient outcomes by providing more effective and disease-modifying treatments.
Target Audience
The primary target audience includes individuals with type 2 diabetes and acute pancreatitis, as well as healthcare providers specializing in endocrinology and gastroenterology.
Features
- Utilizes aquaporin inhibitors to target specific protein channels.
- Developing oral therapies for convenient administration.
- Focus on addressing the underlying mechanisms of type 2 diabetes and acute pancreatitis.
- Aims to restore fluid balance and reduce inflammation.
- Selective inhibition of specific aquaporin isoforms for targeted treatment.